Illumina, Inc. (NASDAQ:ILMN) Shares Bought by Illinois Municipal Retirement Fund

Illinois Municipal Retirement Fund raised its position in Illumina, Inc. (NASDAQ:ILMN) by 1.0% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 67,357 shares of the life sciences company’s stock after acquiring an additional 646 shares during the period. Illinois Municipal Retirement Fund’s holdings in Illumina were worth $9,001,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in ILMN. Assenagon Asset Management S.A. boosted its holdings in Illumina by 1,169.2% in the 3rd quarter. Assenagon Asset Management S.A. now owns 40,410 shares of the life sciences company’s stock valued at $5,270,000 after purchasing an additional 37,226 shares in the last quarter. Allworth Financial LP lifted its holdings in shares of Illumina by 52.2% in the 3rd quarter. Allworth Financial LP now owns 869 shares of the life sciences company’s stock valued at $113,000 after buying an additional 298 shares during the period. Forsta AP Fonden boosted its stake in shares of Illumina by 10.0% in the third quarter. Forsta AP Fonden now owns 34,000 shares of the life sciences company’s stock valued at $4,434,000 after buying an additional 3,100 shares in the last quarter. Wealth Enhancement Advisory Services LLC grew its holdings in Illumina by 82.2% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 17,776 shares of the life sciences company’s stock worth $2,318,000 after acquiring an additional 8,021 shares during the period. Finally, DekaBank Deutsche Girozentrale raised its position in Illumina by 1.4% in the third quarter. DekaBank Deutsche Girozentrale now owns 102,344 shares of the life sciences company’s stock worth $13,191,000 after acquiring an additional 1,446 shares in the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Illumina Stock Performance

Shares of ILMN opened at $95.73 on Wednesday. Illumina, Inc. has a 1 year low of $91.92 and a 1 year high of $156.66. The company’s 50 day simple moving average is $126.02 and its 200 day simple moving average is $133.80. The company has a market capitalization of $15.16 billion, a price-to-earnings ratio of -12.46, a PEG ratio of 1.60 and a beta of 1.10. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. On average, sell-side analysts predict that Illumina, Inc. will post 4.51 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have recently weighed in on ILMN. Piper Sandler upped their price target on shares of Illumina from $185.00 to $190.00 and gave the stock an “overweight” rating in a research note on Monday, February 10th. JPMorgan Chase & Co. upped their target price on shares of Illumina from $125.00 to $140.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. UBS Group increased their target price on shares of Illumina from $133.00 to $145.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. Robert W. Baird upped their price target on Illumina from $124.00 to $139.00 and gave the stock a “neutral” rating in a report on Wednesday, November 6th. Finally, Royal Bank of Canada reduced their price objective on Illumina from $250.00 to $247.00 and set an “outperform” rating for the company in a report on Friday, February 7th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $159.45.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.